Solarek et al. [36] observed downregulated IR expression in RCC cancer cells and they provided evidence that IGF signalling in RCC was predominantly mediated by circulating ligand proteins (IGF-1 and IGF-2) originating from sources other than RCC tumour itself. The gene discussed is IGF2; the disease is renal cell adenocarcinoma.